TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00062868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Expansion Group C)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2
Study: NCT03824236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (SB257049)
Description: Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
Study: NCT04147533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
Study: NCT01175070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of pegaptanib sodium
Description: Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
Study: NCT03484000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Based Cancer Recovery (MBCR)
Description: MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online Mindfulness Based Cancer Recovery (MBCR)
Description: MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
Study: NCT05104931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanoformed Piroxicam IR Tablet
Description: Orally delivered Nanoformed Piroxicam
Study: NCT02811341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Hydrobromide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT05104931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoformed Piroxicam IR Tablet
Description: Orally delivered Nanoformed Piroxicam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felden (piroxicam) Tablets
Description: orally delivered Felden (reference) tablets
Study: NCT03636230

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: In-Clinic visits only
Study: NCT01940744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prescriptive Mobilization
Description: The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pragmatic Mobilization
Description: The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
Study: NCT02419911

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic surgery
Description: gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
Study: NCT05104931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexidol (piroxicam) Tablets
Description: orally delivered Brexidol (reference) tablets
Study: NCT02719951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPEB PET imaging
Description: PET exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPEB PET imaging
Description: PET exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPEB PET imaging
Description: PET exam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood sample and urine sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood sample and urine sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood sample and urine sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam
Study: NCT01416909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laxative Treatment
Description: Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laxative Treatment
Description: Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
Study: NCT03457402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shaping Delay Tolerance
Description: Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shaping Delay Tolerance
Description: Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
Study: NCT01416909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laxative Treatment
Description: Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
Study: NCT03868631

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein supplement
Description: 19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
Study: NCT01416909

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment Questionnaires
Description: Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
Study: NCT03491124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Up to five small ASP needles placed in each ear until pain is reduced to 1/10.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Laser pointer pointed at the ear, but not turned on.
Study: NCT06276595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)
Description: The TODOS program consists of 11 weekly sessions conducted with girls ages 8-11 and their female caregivers. Five of the 11 sessions will be taught to small groups, and 6 of the Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control condition - 3 Monthly Group Activities in the Community
Description: The control condition consists of 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre The third group session will consist of going bowling at the local bowling alley.
Study: NCT03882515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Continuous Surface Slip Technique
Description: 1. Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~2. Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~3. Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without intervention
Description: Evaluation and re-evaluation without intervention
Study: NCT05013164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks
Study: NCT04478123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
Study: NCT02435329

Intervention type: OTHER
Intervention: Baseline comparison of microcirculation and bone metabolism
Description: Baseline comparison of microcirculation and bone metabolism among the 5 different groups

Intervention type: OTHER
Intervention: Baseline comparison of microcirculation and bone metabolism
Description: Baseline comparison of microcirculation and bone metabolism among the 5 different groups

Intervention type: OTHER
Intervention: Baseline comparison of microcirculation and bone metabolism
Description: Baseline comparison of microcirculation and bone metabolism among the 5 different groups

Intervention type: OTHER
Intervention: Baseline comparison of microcirculation and bone metabolism
Description: Baseline comparison of microcirculation and bone metabolism among the 5 different groups

Intervention type: OTHER
Intervention: Baseline comparison of microcirculation and bone metabolism
Description: Baseline comparison of microcirculation and bone metabolism among the 5 different groups
Study: NCT03457688

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: prebiotic inulin-type fructans

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo maltodextrin
Study: NCT03868631

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein supplement
Description: 26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
Study: NCT02707276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low Field Magnetic Stimulation
Description: The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low Field Magnetic Stimulation
Description: The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
Study: NCT03702816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE180 PET Scan
Description: GE180 PET Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE180 PET Scan
Description: GE180 PET Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE180 PET Scan
Description: GE180 PET Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE180 PET Scan
Description: GE180 PET Scan
Study: NCT01181830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium pidolate
Description: administration of 8.1 mmol bid of magnesium pidolate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of 8.1 mmol bid of placebo
Study: NCT00089973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispinesib
Description: Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
Study: NCT01223027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
Study: NCT04216719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCM-RISE
Description: OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
Study: NCT04334525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice architecture + repeated exposure
Description: Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period.
Study: NCT02414672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareSTEPS
Description: Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
Study: NCT01223027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
Study: NCT00691756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold blood renal perfusion
Description: Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid renal perfusion
Description: Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
Study: NCT02287220

Intervention type: DEVICE
Intervention: Non-Contact Oximetry
Description: Video Record subject when subjected to small amounts of near infrared light
Study: NCT01420614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral approach
Description: diagnostic and interventional procedures by femoral artery access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial approach
Description: diagnostic and interventional procedures by radial artery access
Study: NCT02223169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg albumin-derived peptide
Description: Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg albumin-derived peptide
Description: Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
Study: NCT04158427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal transplantation
Description: Faecal transplantation from a healthy donor via colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo faecal transplantation
Description: Placebo faecal transplantation containing patient's own feces via colonoscopy